v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2025
Jun. 30, 2024
Jun. 30, 2023
Current assets      
Cash $ 230,392 $ 661,415 $ 4,492,292
Accounts receivable, net 180,897 606,885 1,125,394
Inventory, net 1,324,540 1,431,556 4,804,299
Due from Bloomios   0 845,443
Due from VitaMedica transition 0 212,358 0
Prepaid expenses and other receivables 232,328 502,188 1,112,280
Assets available for sale - Interactive offers current   0 89,989
Assets available for sale - Building 0 4,005,516 4,611,248
Assets available for sale - VitaMedica current   0 2,599,934
Assets available for sale - E-core current   0 10,332,105
Purchase price receivable - VitaMedica 2,000,000 2,000,000 0
Purchase price receivable - E-core 0 2,000,000 0
Total current assets 3,968,157 11,419,918 30,012,984
Property and equipment, net 1,972,522 2,356,556 2,831,375
Intangible assets, net 182,300 239,871 6,924,982
Goodwill 848,854 848,854 2,886,309
Deferred tax asset 5,948,858 5,948,858 5,604,056
Digital assets 44,732 0  
Other assets 192,122 278,435 76,728
Discontinued assets available for sale - Interactive offers   0 936,054
Discontinued assets available for sale - VitaMedica   0 2,051,214
Discontinued assets available for sale - E-core   0 12,067,333
Right-of-use asset, net 1,909,769 2,418,596 410,453
Total other assets 11,099,157 12,091,170 33,788,504
Total assets 15,067,314 23,511,088 63,801,488
Current liabilities      
Accounts payable 1,414,929 481,647 1,028,611
Accrued compensation 1,098,146 1,098,856 533,842
Deferred revenue 23,914 235,255 0
Accrued liabilities 223,535 736,407 2,439,794
Accrued interest 834,056 476,018 655,187
Acquisition payable 260,652 413,152  
Related party advances, net 75,000 100,000  
Acquisition payable   413,152 152,500
Current portion of note payable 420,000 0 338,474
Current portion of acquisition note payable - E-core   0 5,656,620
Current portion of Cygnet subsidiary notes payable 5,380,909 5,447,565 795,778
Note payable on building for sale 0 2,634,538  
Discontinued liabilities - Interactive offers   0 792,408
Discontinued liabilities - VitaMedica   0 617,174
Discontinued liabilities - E-core   0 3,401,983
Current portion of operating lease payable 165,060 1,031,714 454,127
Related party advances, net   100,000 0
Current portion of related party note payable 375,000 0 1,429,356
Current portion of convertible notes payable 525,000 0 1,254,167
Note payable on building for sale   2,634,538 2,841,566
Note payable   557,429 173,812
Related party note payable   500,000 0
Convertible notes payable   1,550,000 895,833
Total current liabilities 10,796,201 12,655,152 22,391,587
Operating lease payable, net of current portion 1,844,233 1,732,606 0
Total current liabilities 10,796,201 12,655,152 22,391,587
Related party note payable 125,000 500,000  
Note payable 140,000 557,429 4,898,548
Convertible notes payable 311,170 1,550,000  
Acquisition note payable - E-core   0 7,605,085
Total long-term liabilities 2,420,403 4,340,035 13,573,278
Commitments and contingencies      
Total long-term liabilities 2,420,403 4,340,035 13,573,278
Stockholders' equity      
Preferred stock, $0.001 par value, 100,000,000 shares authorized, and 25,000 and 25,000 shares issued and outstanding, respectively 150 25 25
Common stock, $0.001 par value, 100,000,000 shares authorized, and 1,430,429 and 1,045,429 shares issued and outstanding, respectively 1,430 1,045 1,011
Additional paid in capital 55,467,290 53,374,444 51,541,909
Accumulated deficit (53,618,160) (46,859,613) (23,201,175)
Total stockholders' equity 1,850,710 6,515,901 27,836,623
Non-controlling interest in subsidiary     (505,147)
Total stockholders' equity attributable to Upexi, Inc. 1,850,710 6,515,901 27,836,623
Total liabilities and stockholders' equity 15,067,314 23,511,088 63,801,488
Total liabilities and stockholders' equity $ 15,067,314 $ 23,511,088 $ 63,801,488